Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake

Company Overview - Viridian Therapeutics is a clinical-stage biotechnology company focused on developing innovative antibody-based therapies, particularly for thyroid eye disease [6] - The company utilizes monoclonal antibody engineering to advance its pipeline and address unmet medical needs in rare disorders [6] - As of February 17, 2026, Viridian's market capitalization is $2.30 billion, with a revenue of $70.79 million and a net income of -$301.97 million [4] Recent Developments - On February 17, 2026, Commodore Capital disclosed the sale of its entire 3,200,000-share position in Viridian Therapeutics, amounting to approximately $69.06 million [1][2] - This liquidation reduced Viridian's weighting in Commodore's portfolio from 3.4% to zero [7] - Following the sale, Viridian's shares were priced at $28.29, reflecting a 75% increase over the past year, outperforming the S&P 500 [7][10] Future Prospects - Viridian is entering 2026 with significant potential catalysts, including the FDA's acceptance of veligrotug's BLA for thyroid eye disease, with a PDUFA date set for June 30 [10] - The company has approximately $888 million in cash and investments, indicating a strong financial position to fund operations until profitability [10] - The removal of Commodore's stake may suggest a strategic shift towards other investments or a response to valuation considerations, as Viridian approaches a catalyst-heavy year [11]